Eagle Pharmaceuticals

209 articles with Eagle Pharmaceuticals

• Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin

  6/17/2021

  Eagle Pharmaceuticals, Inc. announced that it has responded to the Complete Response Letter for its Abbreviated New Drug Application for vasopressin received from the U.S. Food and Drug Administration in February 2021.

• Eagle Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021

  5/26/2021

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference 2021

•  Eagle Pharmaceuticals Reports First Quarter 2021 Results

  5/10/2021

  Expects approximately $20-$25 million from combined royalty and milestone revenue in 2022 for TREAKISYM (bendamustine) Ready-to-Dilute (“RTD”) and Rapid Infusion (“RI”) formulations

• Eagle Pharmaceuticals Announces Filing of TREAKISYM (bendamustine) Rapid Infusion (“RI”) Liquid Formulation in Japan

  5/10/2021

  Eagle expects approximately $20-$25 million from combined royalty and milestone revenue in 2022 for TREAKISYM (bendamustine) Ready-to-Dilute (“RTD”) and Rapid Infusion (“RI”) formulations

• Eagle Pharmaceuticals Appoints Former FDA Official and Public Health Expert Dr. Luciana Borio to its Board of Directors

  5/3/2021

  Eagle Pharmaceuticals, Inc. announced the appointment of Luciana Borio, MD, to its Board of Directors.

• Eagle Pharmaceuticals Announces TREAKISYM (bendamustine) Ready-to-Dilute (“RTD”) Formulation

  4/30/2021

  -Eagle believes new indication could allow for a significant expansion of the overall market opportunity- -RTD and Rapid Infusion (“RI”) formulations anticipated to generate approximately $25 million of combined royalty and milestone revenue at peak-

• Eagle Pharmaceuticals to Host First Quarter 2021 Financial Results on May 10, 2021

  4/29/2021

  Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 first quarter financial results on Monday, May 10, 2021, before the market opens.

• Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results and Provides Pipeline Review

  3/2/2021

  Eagle Pharmaceuticals, Inc. announced financial results for the three and twelve months ended December 31, 2020, and reviewed key pipeline programs.

• Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results and Pipeline Review on March 2, 2021

  2/22/2021

  Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 fourth quarter and full year financial results on Tuesday, March 2, 2021, before the market opens.

• Eagle Pharmaceuticals Receives Additional FDA Questions Regarding Vasopressin; Court Date Set for July 7, 2021 in Vasopressin Trial

  2/2/2021

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for its Abbreviated New Drug Application (“ANDA”) for vasopressin. Eagle has now had two conversations with FDA regarding the CRL and will have an additional meeting with FDA

• 

  FDA to Require Additional Study for Eagle’s Generic Vasopressin

  2/2/2021

  Eagle Pharmaceuticals is still struggling to get its generic vasopressin to market, announcing both a regulatory stall and an additional trial delay for a patent case with Endo Par Innovation Company over the drug.

• Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed

  2/1/2021

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 29, 2021, the United States District Court for the District of Delaware (the “Court”) postponed the February 1, 2021 vasopressin trial between Eagle and Endo Par Innovation Company, LLC, et al.

• Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns

  1/11/2021

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 8, 2021, the United States District Court for the District of Delaware postponed the January 11, 2021 vasopressin trial between Eagle and Endo Par Innovation Company, LLC, et al. due, in part, to ensure the health and safety of the trial teams in light of a COVID-19 concern.

• Eagle Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/4/2021

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference as follows: Date: Wednesday, January 13, 2021 Time: 4:30 p.m. Eastern Standard Time

• Eagle Pharmaceuticals’ Presentation at Piper Sandler 32nd Annual Virtual Healthcare Conference Available for Viewing

  11/23/2020

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company’s pre-recorded presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference

• Eagle Pharmaceuticals Reports Third Quarter 2020 Results

  11/2/2020

  Q3 2020 net income was $0.52 per basic and $0.51 per diluted share and adjusted non-GAAP net income was $1.19 per basic and $1.17 per diluted share

• Eagle Pharmaceuticals Strengthens Management Team to Prepare for Future Growth

  11/2/2020

  Key additions deepen scientific, analytics and commercial expertise; positions Eagle to advance product pipeline and prepare for future commercial launches in oncology and critical care businesses

• Eagle Pharmaceuticals to Discuss Third Quarter 2020 Financial Results on November 2, 2020

  10/26/2020

  Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 third quarter financial results on Monday, November 2, 2020, before the market opens. Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results as follows: Date Monday, November 2, 2020

• Eagle Pharmaceuticals Commences $25 Million Accelerated Share Repurchase as Part of Existing $160 Million Share Repurchase Program

  9/24/2020

  Eagle Pharmaceuticals, Inc. announced that its Board of Directors has approved a $25 million accelerated share repurchase transaction with JPMorgan Chase Bank, National Association as part of the Company’s existing $160 million share repurchase program.

• Eagle Pharmaceuticals’ Japanese Licensing Partner, SymBio, Receives Approval of TREAKISYM Ready-To-Dilute (“RTD”) Formulation, with Launch Expected in January 2021

  9/23/2020

  Eagle Pharmaceuticals, Inc. announced that its marketing partner, SymBio Pharmaceuticals Limited, has received regulatory approval for TREAKISYM ready-to-dilute liquid formulation from the Pharmaceuticals and Medical Devices Agency in Japan.